slide1
Download
Skip this Video
Download Presentation
CASE PRESENTATION

Loading in 2 Seconds...

play fullscreen
1 / 45

CASE PRESENTATION - PowerPoint PPT Presentation


  • 128 Views
  • Uploaded on

CASE PRESENTATION. CC: Jaundice HPI: 64-yr-old man 4 wk h/o anorexia & 15 lb wt loss 2 wk h/o pruritus dark urine abdominal pain, midepigastric, dull, constant with radiation to the back 2 days earlier a family members notes jaundice. CASE PRESENTATION.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'CASE PRESENTATION' - bennett


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
case presentation
CASE PRESENTATION

CC: Jaundice

HPI: 64-yr-old man

  • 4 wk h/o anorexia & 15 lb wt loss
  • 2 wk h/o
    • pruritus
    • dark urine
    • abdominal pain, midepigastric, dull, constant with radiation to the back
  • 2 days earlier a family members notes jaundice
case presentation3
CASE PRESENTATION

PMH: DM, type 2 (dx’d 6 yrs ago)

PSH: None

Meds: glyburide

ALL: NKDA

SH: Married. No EtOH or tobacco

FH: No malignancies

case presentation4
CASE PRESENTATION

Physical Exam

Vitals: 120/83 65 12 AF 176 lbs

Gen: NAD.

Heent: Icteric. OP nl.

Neck: Supple. No LAD.

Lungs: CTA.

Heart: RRR w/o m/r/g.

Abd: NABS. Tender MEG. Palpable non- tender gallbladder.

Ext: No c/c/e.

case presentation5
CASE PRESENTATION

Laboratory Data

TBili 8.5

Alk phos 350

AST 78

ALT 90

Albumin 3.0

Hgb 10.5

2005 estimated us cancer cases
2005 Estimated US Cancer Cases

Men710,040

Women662,870

Prostate 33%

Lung and bronchus 13%

Colon and rectum 10%

Urinary bladder 7%

Melanoma of skin 5%

Non-Hodgkin 4% lymphoma

Kidney 3%

Leukemia 3%

Oral Cavity 3%

Pancreas 2%

All Other Sites 17%

32% Breast

12% Lung and bronchus

11% Colon and rectum

6% Uterine corpus

4% Non-Hodgkin lymphoma

4% Melanoma of skin

3% Ovary

3% Thyroid

2% Urinary bladder

2% Pancreas

21% All Other Sites

*Excludes basal and squamous cell skin cancers and in situ carcinomas except urinary bladder.

Source: American Cancer Society, 2005.

pancreas
Pancreas
  • Acinar cells 80%
  • Ductal cells 10-15%
  • Endocrine cells 1-2%
pancreatic cancer
Pancreatic Cancer
  • Endocrine
    • 1 to 2%
  • Exocrine
    • > 95%
    • 85 to 90% ductal origin
      • Head 60-70%
      • Body 5-10%
      • Tail 10-15%
pancreatic cancer who classification exocrine
Pancreatic CancerWHO Classification - Exocrine
  • Malignant
    • Ductal adenocarcinoma
    • Osteoclast-like giant cell tumor
    • Serous cystadenocarcinoma
    • Mucinous cystadenocarcinoma
    • Intraductal papillary mucinous carcinoma
    • Acinar cell carcinoma
    • Pancreatoblastoma
    • Solid-pseudopapillary carcinoma
    • Miscellaneous carcinoma
pancreatic cancer risk factors
Pancreatic CancerRisk Factors
  • Tobacco (RR 1.5 – 3)
  • Family history (7-10%)
    • 1st degree relative: RR 3-5
  • Familial syndromes
    • Hereditary pancreatitis (AD, cationic trypsinogen gene)
      • 40% by age 70, up to 75% if paternal
    • Peutz-Jeghers
    • Von Hippel-Lindau
    • Familial atypical multiple-mole melanoma (FAMMM)
    • Ataxia-telangiectasia
    • FAP, HNPCC
  • Chronic pancreatitis (RR up to 16)
  • Diabetes mellitus, type II (RR 2 if DM present > 5 yrs)
  • Others: Obesity, inactivity, diet

Michaud DS. Gastrointest Endosc 2002;56:S195-200.

pancreatic carcinogenesis
Pancreatic Carcinogenesis
  • Activation of oncogenes
  • Inactivation of tumor suppressor genes
  • Defects in DNA mismatch repair genes
pancreatic cancer presentation
Pancreatic CancerPresentation
  • Symptoms & signs
    • Jaundice, pruritus, acholic stool
    • Abdominal pain
    • Back pain
    • Weight loss, anorexia, nausea & vomiting
    • Curvoisier’s sign: palpable non-tender gallbladder
  • Acute pancreatitis
  • New onset diabetes
  • Pancreatic exocrine insufficiency
pancreatic cancer diagnostic evaluation
Pancreatic CancerDiagnostic Evaluation
  • Laboratory
    • Tumor markers
  • Radiology
    • Computed Tomography Scan
    • Magnetic Resonance Imaging (MRI/MRCP)
    • Positron Emission Tomography
    • Percutaneous Transhepatic Cholangiography (PTC)
  • Endoscopy
    • Endoscopic Retrograde Cholangiopancreatography (ERCP)
    • Endoscopic Ultrasound (EUS)
ca 19 9 tumor associated antigen
CA 19-9 Tumor-Associated Antigen
  • Synthesized by pancreatic and biliary ductal cells
  • Lewis A blood group
  • 5% of population is Lewis A-B- and cannot synthesize CA 19-9
  • Upper limit of normal 37 U/ml
    • Sensitivity 81%
    • Specificity 90%
  • False elevation: cholangitis
  • CA 19-9 > 1000 predicts unresectability
  • Predicts recurrence

Steinberg W. Am J Gastroenterol 1990;85:350-5.

pancreatic cancer ct scan
Pancreatic CancerCT Scan

Pancreas protocol

  • Thin cuts
  • PO/IV contrast
  • First (pancreas) phase
    • 40s after IV contrast
    • Max. enhancement of normal pancreas
  • Second (portal vein) phase
    • 70s after IV contrast
    • Liver metastases
    • Tumor involvement of portal & mesenteric veins
pancreatic cancer ercp
Pancreatic CancerERCP
  • Diagnostic
    • Pancreatic ductal abnormalities
    • Tissue (brushings)
      • Sens 18-60%, Spec 99%
  • Therapeutic
    • Biliary drainage
      • Plastic stent
      • Metal stent
endoscopic ultrasound
Endoscopic Ultrasound
  • Developed to overcome limitations of transabdominal ultrasound
    • intervening structures
    • limited resolution
  • Transducer placed at distal end of side-viewing endoscope
endoscopic ultrasound22
Endoscopic Ultrasound

Radial

Linear

100°

360°

pancreatic cancer endoscopic ultrasound
Pancreatic CancerEndoscopic Ultrasound
  • Tumor staging
    • more accurate than helical CT in small lesions and assessing local extent, lymph nodes, & vascular invasion
    • CT better for distant metastases
    • better than angiography
    • ? MRI, MRCP, PET scan
  • Diagnostic – Fine Needle Aspiration (FNA)
    • Sensitivity 85%
    • Specificity 99%
pancreatic cancer26
Pancreatic Cancer

SUSPICION OF PANCREATIC CANCER

Helical CT Scan

Pancreatic head

tumor < 2 cm

Pancreatic head

tumor > 2 cm

Tumor of body or

tail of the pancreas

No tumor

ERCP

EUS

Laparoscopy with

cytology of washings

if +

if -

Surgical exploration for resection

pancreatic cancer palliative issues
Pancreatic CancerPalliative Issues
  • Jaundice
    • ERCP, PTC, or surgery
  • Pain
    • Radiation therapy
    • Celiac axis neurolysis
      • Surgical, fluoroscopic- or EUS-guided
  • Duodenal obstruction
    • Surgery or metal stent
endoscopic stents
Endoscopic Stents
  • Plastic stents: polyethylene
    • Drainage prior to surgery
    • Up to 11.5 Fr
    • Life span < 3 months
    • $100
  • Metal stents: self-expanding metal stents (SEMS)
    • Palliative
    • 10 mm or 30 Fr
    • Longer patency
    • Life span > 3 months
    • $1,000
ercp stent v surgical bypass palliation of biliary obstruction in pancreatic cancer
ERCP Stent v Surgical Bypass Palliation of Biliary Obstruction in Pancreatic Cancer

Flamm CR et al. Gastrointest Endosc 2002;56(6):S218-25.

plastic v metal stent palliation of biliary obstruction in pancreatic cancer
Plastic v Metal Stent Palliation of Biliary Obstruction in Pancreatic Cancer

Levy MJ et al. Clin Gastroenterol Hepatol. 2004 Apr;2(4):273-85.

screening for pancreatic cancer
Screening for Pancreatic Cancer

No guidelines or recommendations

Studies in progress – Univ. Washington & Johns Hopkins

  • Who
    • High-risk individuals
  • When
    • Age 40 yrs or 10 yrs younger than the youngest family member with PC
  • How
    • Serology: Genetic and protein markers
    • Radiology: CT, MRI/MRCP
    • Endoscopy: EUS, ERCP
pancreatic cancer ajcc staging
Pancreatic CancerAJCC Staging

Primary Tumor (T)

T1 Limited to pancreas, < 2 cm

T2 Limited to pancreas, > 2 cm

T3 Extension into duodenum, CBD

T4 Extension into vessels (not splenic),

stomach, spleen, or colon

Regional Lymph Nodes (N)

N0 None

N1 Regional nodal metastases

Distant Metastases (M)

M0 None

M1 Distant metastases

biliary tract cancer
Biliary Tract Cancer
  • Gallbladder
  • Extrahepatic bile duct
  • Ampulla of Vater
gallbladder cancer
Gallbladder Cancer
  • 2.5 cases per 100,000
  • 5th most common GI cancer
  • 6,500 deaths/year
  • M:F 1:3
  • Risk factors
    • Gallstones
    • Porcelain gallbladder
    • Chronic typhoidal carrier
  • Presentation
    • Pain, jaundice
    • 1-2% of resected gallbladders
  • 5 YR Survival: 5%
  • Highest incidences (7-20/100,000)
  • Native Americans (North & South)
  • Poland
  • Northern India
cholangiocarcinoma
Cholangiocarcinoma
  • 1 case per 100,000
  • Slight M>F
  • Risk factors
    • Primary sclerosing cholangitis (PSC)
    • Choledochal cysts
    • Clonorchis sinensis
    • Hepatolithiasis
    • CBD stones
    • Thorium dioxide (Thorotrast)
cholangiocarcinoma40
Cholangiocarcinoma

MRCP of PSC

  • Presentation
    • Obstructive jaundice
  • Diagnosis
    • Tumor markers
      • CA 19-9 (85%)
      • CEA (35%)
      • CA 125 (30-50%)
    • ERCP/MRCP
    • CT scan
  • Treatment
    • Surgery
  • Palliation
    • Biliary drainage
  • 5 YR Survival: 5%

ERCP

ampullary cancer
Ampullary Cancer
  • 3 cases per 1 million
  • Risk factors
    • FAP
    • Peutz-Jeghers
  • Presentation
    • Jaundice
    • “Silver stool”
  • Diagnosis/Staging
    • EGD, CT, EUS, ERCP
  • Treatment: Surgery
  • 5 YR Survival: 25 – 40%
outcome of patients after pancreaticoduodenectomy
Outcome of Patients after Pancreaticoduodenectomy

Sarmiento JM, et al. Surg Clin North Am 2001.

ad